Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging
| العنوان: | Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging |
|---|---|
| المؤلفون: | Michael Federle, Judith Chezmar, Daniel L. Rubin, Jeffrey Weinreb, Patrick Freeny, Udo P. Schmiedl, Jeffrey J. Brown, Joseph A. Borrello, Joseph K.T. Lee, Richard C. Semelka, Robert Mattrey, Abraham H. Dachman, Sanjay Saini, Steven E. Harms, Donald G. Mitchell, Mark W. Anderson, Hollis H. Halford, William F. Bennett, Stuart W. Young, Matthew Rifkin, Spencer B. Gay, Rocco Ballerini, Paul F. Sherwin, Ronald O. Robison |
| المصدر: | Journal of Magnetic Resonance Imaging. 12:689-701 |
| بيانات النشر: | Wiley, 2000. |
| سنة النشر: | 2000 |
| مصطلحات موضوعية: | Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, MRI contrast agent, Contrast Media, Phases of clinical research, Sensitivity and Specificity, Diagnosis, Differential, Liver disease, medicine, Mangafodipir, Humans, Radiology, Nuclear Medicine and imaging, Medical diagnosis, Edetic Acid, Aged, Aged, 80 and over, medicine.diagnostic_test, business.industry, Liver Neoplasms, Magnetic resonance imaging, Gold standard (test), Middle Aged, Image Enhancement, medicine.disease, Magnetic Resonance Imaging, Pyridoxal Phosphate, Injections, Intravenous, Female, Radiology, business, medicine.drug |
| الوصف: | The efficacy of contrast-enhanced magnetic resonance imaging (MRI) for detecting and characterizing, or excluding, hepatic masses was assessed in 404 patients, following the intravenous administration of mangafodipir trisodium (MnDPDP) injection, a hepatic MRI contrast agent. An initial contrast-enhanced computed tomography (CT) examination was followed by unenhanced MRI, injection of MnDPDP (5 μmol/kg IV), and enhanced MRI at 15 minutes post injection. Agreement of the radiologic diagnoses with the patients' final diagnoses was higher for enhanced MRI and for the combined unenhanced and enhanced MRI evaluations than for unenhanced MRI alone or enhanced CT using the clinical diagnosis as the gold standard. Mangafodipir-enhanced MRI uniquely provided additional diagnostic information in 48% of the patients, and patient management was consequently altered in 6% of the patients. MnDPDP-enhanced MRI was comparable or superior to unenhanced MRI and enhanced CT for the detection, classification, and diagnosis of focal liver lesions in patients with known or suspected focal liver disease. J. Magn. Reson. Imaging 2000;12:689–701. © 2000 Wiley-Liss, Inc. |
| تدمد: | 1522-2586 1053-1807 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0bbba3ba8770f898efc607cc08d3be https://doi.org/10.1002/1522-2586(200011)12:5<689::aid-jmri5>3.0.co;2-z |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....5f0bbba3ba8770f898efc607cc08d3be |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15222586 10531807 |
|---|